42. EFFICACY OF XUEFU ZHUYU DECOCTION FOR TREATMENT OF MODERATE TO SEVERE CANCER PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS
Main Article Content
Abstract
This systematic review and meta-analysis evaluates efficacy of Xuefu Zhuyu decoction in patients with moderate to severe cancer pain. Four databases, including PubMed, Cochrane Library, CNKI and Wanfang Data, were searched from inception through 2024 August 8th. We selected randomized controlled trials that studied patients with moderate to severe cancer pain and compared plus Opioids versus Opioids alone. Outcomes were incidence of pain relief and pain intensity. Risk ratio (RR) or standardized mean difference (SMD) with 95% confidence interval (CI) were used to evaluate treatment effects. A total of 8 RCT with 448 patients in Xuefu Zhuyu decoction group and 446 patients in opioid group were included. Compared with opioid group, Xuefu Zhuyu decoction group had a higher incidence of pain relief (RR = 1,27; 95%CI = 1,17 to 1,39; p < 0,001) and lower pain intensity (SMD = -1,28; 95%CI = -2,13 to -0,42; p < 0,001). Xuefu Zhuyu decoction in combination with Opioids improved pain relief in patients with moderate to severe cancer pain compared to Opioids alone.
Keywords: Xuefu zhuyu decoction, traditional medicine, cancer pain, meta-analysis.
Article Details
Keywords
Xuefu zhuyu decoction, traditional medicine, cancer pain, meta-analysis
References
[2] Nathan J.N, Shereef M.E, Ricardo H.A, Cancer pain: a review of epidemiology, clinical quality and value impact, Future Oncology, 2016, 13 (9): 833-841.
[3] Corli O, Floriani I, Roberto A et al, Are strong Opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to Opioids, Annals of Oncology, 2016, 27 (6): 1107-1115.
[4] Swegle J.M, Logemann C, Management of common opioid-induced adverse effects, American family physician, 2006, 74 (8): 1347-1354.
[5] 李应宏, 张宇杰, 刘生永, 王沛, 沈海霞, 刘金鑫. 血府逐瘀汤联合盐酸羟考酮缓释片治疗血瘀型癌痛的疗效观察, 内科, 2017, 12 (05): 605-608 + 611, doi:10.16121/j.cnki.cn45-1347/r.2017.05.01.
Lý Anh Hùng, Trương Vũ Nhiên, Lưu Sinh Mạch, Vương Phái, Trầm Hải Hà, Lưu Kim Hâm, Quan sát hiệu quả lâm sàng của Huyết phủ trục ứ thang kết hợp với Oxycodone Hydrochlorid trong điều trị đau do ung thư thể huyết ứ, Nội khoa, 2017, 12 (05): 605-608 + 611, doi:10.16121/j.cnki.cn45-1347/r.2017.05.01.
[6] 李秋荐. 血府逐瘀汤对气虚血瘀型癌症患者癌性疼痛的影响. 北方药学, 2018;15(4):91, doi:10.3969/j.issn.1672-8351.2018.04.073.
Lí Thu Kiện, Ảnh hưởng của Huyết phủ trục ứ thang trên bệnh nhân đau do ung thư thể khí suy huyết ứ, Dược học Bắc Kinh, 2018, 15 (4): 91, doi:10.3969/j.issn.1672-8351.2018.04.073.
[7] 郑巧, 周铁成, 向生霞. 血府逐瘀汤治疗晚期肺癌瘀血阻络证癌痛患者的临床研究. 中药药理与临床, 2022, 38 (02): 195-198, doi:10.13412/j.cnki.zyyl.2022.02.024.
Trịnh Xảo, Chu Thiết Thành, Hướng Sinh Hà, Nghiên cứu lâm sàng của Huyết phủ trục ứ thang điều trị bệnh nhân ung thư phổi giai đoạn muộn chứng ứ huyết, Lâm sàng và dược lý thuốc y học cổ truyền, 2022, 38 (02): 195-198, doi:10.13412/j.cnki.zyyl.2022.02.024.
[8] Page M.J, McKenzie J.E, Bossuyt P.M et al, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 2021, 372.
[9] Wang Y.H, Chang J.Y, Feng L, Effect of oral Chinese medicine combined with Western medicine on cancer pain: a meta-analysis, Chinese Journal of Integrative Medicine, 2021, 27: 713-720.
[10] Liu C, Liu D.Q, Tian Y.K et al, The emerging role of quercetin in the treatment of chronic pain, Current Neuropharmacology, 2022, 20 (12): 2346.
[11] 林平冬, 翁霞萍, 刘发元, 刘献祥, 李西海, 叶蕻芝. 牛膝有效成分防治骨关节炎的作用机制探讨. 风湿病与关节炎, 2015, 4 (02): 56-59.
Lâm Bình Đông, Ông Hà Bình, Lưu Phát Nguyên, Lưu Hiến Tường, Lý Tây Hải, Hiệp Hồng Chi, Khảo sát cơ chế tác động của các thành phần hiệu quả từ ngưu tất trong việc phòng ngừa và điều trị viêm khớp, Viêm xương và bệnh phong thấp, 2015, 4 (02): 56-59.
[12] Wang Y, Jia Q, Zhang Y, Wei J, Liu P, Taoren Honghua Drug Attenuates Atherosclerosis and Plays an Anti-Inflammatory Role in ApoE Knock-Out Mice and RAW264.7 Cells, Frontiers in pharmacology, 2020, 11: 1070, doi:10.3389/fphar.2020.01070.
[13] Zhu M.D, Zhao L.X, Wang X.T, Gao Y.J, Zhang Z.J, Ligustilide inhibits microglia-mediated proinflammatory cytokines production and inflammatory pain. Brain Research Bulletin, 2014, 109: 54-60.